DOCSLIB.ORG

New ATC Codes and New Ddds to Be Included in the 2019 Edition of the ATC/DDD Index Are Also Enclosed

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New ATC Codes and New Ddds to Be Included in the 2019 Edition of the ATC/DDD Index Are Also Enclosed WHO COLLABORATING CENTRE FOR DRUG STATISTICS METHODOLOGY To the users of the ATC/DDD system 26 November 2018 Dear all, ATC/DDD alterations and new ATC/DDDs – valid from January 2019 Enclosed please find the lists of ATC and DDD alterations valid from January 2019. Lists of new ATC codes and new DDDs to be included in the 2019 edition of the ATC/DDD Index are also enclosed. ATC alterations Only one ATC alteration is made. The ATC code for dimethyl fumarate is changed from N07XX09 to L04AX07 in order to cover both approved indications, i.e. multiple sclerosis and plaque psoriasis. DDD alterations DDDs for several antibacterials for systemic use (J01) have been altered. In addition the DDD for aprepitant (A04AD12) have been altered from 95 mg (O,P) to 165 mg (O) and 150 mg (P). The new DDDs are based on the single dose treatment on day one. Updated versions of the ATC/DDD Index and the Guidelines for ATC classification and DDD assignment will be distributed in January 2019. These publications are available in English and Spanish. Please find the order form on our website www.whocc.no. If you need further information, please feel free to contact us ([email protected]). For your information, the next course in the ATC/DDD methodology will be arranged in Oslo 13-14 June 2019. Please see the enclosed invitation. You will be able to make your registration from February. Yours sincerely, Irene Litleskare Enclosures Postal address: Office address: Telephone: + 47 21 07 81 60 P.O.Box 222 Skøyen Sandakerveien 24C, Bygg C N-0213 Oslo N-0473 Oslo E-mail: [email protected] ALTERATIONS IN ATC CLASSIFICATION valid from January 2019 sorted according to previous ATC code Previous ATC code ATC level name New ATC code N07XX09 dimethyl fumarate L04AX07 WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 Other alterations in ATC classification, i.e. new levels (this list includes only new levels assigned in connection with an alteration), deleted levels and altered names of ATC levels valid from January 2019 sorted according to ATC code ATC code Previous ATC level name New ATC level name or new ATC level A12BA30 combinations potassium (different salts in combination) C09C Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09CA Angiotensin II antagonists, plain Angiotensin II receptor blockers (ARBs), plain C09D Angiotensin II antagonists, combinations Angiotensin II receptor blockers (ARBs), combinations C09DA Angiotensin II antagonists and diuretics Angiotensin II receptor blockers (ARBs) and diuretics C09DB Angiotensin II antagonists and calcium Angiotensin II receptor blockers (ARBs) channel blockers and calcium channel blockers C09DX Angiotensin II antagonists, other Angiotensin II receptor blockers (ARBs), combinations other combinations D08AK04 mercurochrome merbromin L01XC16 dinutuximab dinutuximab beta L01XC29 ermekumab bermekimab V09IX07 fluoromethylcholine (18F) fluorocholine (18F) WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 ALTERATIONS IN DDDs valid from January 2019 ATC code ATC level name - Previous DDD New DDD A04AD12 aprepitant 1) 95 mg P 150 mg P A04AD12 aprepitant 95 mg O 165 mg O H01BA01 vasopressin (argipressin) 4 U P 40 U P J01CA01 ampicillin 2 g P 6 g P J01CA04 amoxicillin 1 g O 1.5 g O J01CA04 amoxicillin 1 g P 3 g P J01CA17 temocillin 2 g P 4 g P amoxicillin and beta-lactamase J01CR02 1 g O 1.5 g O inhibitor J01DE01 cefepime 2 g P 4 g P J01DH02 meropenem 2 g P 3 g P J01MA02 ciprofloxacin 0.5 g P 0.8 g P J01XB01 colistin 3 MU P 9 MU P 1) Refers to fosaprepitant WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 NEW ATC CODES valid from January 2019 ATC code ATC level name A06AH05 naldemedine A07XA06 crofelemer A10BD23 metformin and ertugliflozin A10BD24 sitagliptin and ertugliflozin A10BD25 metformin, saxagliptin and dapagliflozin A10BH52 gemigliptin and rosuvastatin A10BK04 ertugliflozin A10BK05 ipragliflozin A16AX15 telotristat B01AX07 caplacizumab B02BX07 lusutrombopag B02BX08 avatrombopag B02BX09 fostamatinib B03XA05 roxadustat B06AC05 lanadelumab C01CX09 angiotensin II C02KX52 ambrisentan and tadalafil C09DX05 valsartan and nebivolol C09DX06 candesartan, amlodipine and hydrochlorothiazide D04AX01 doxepin D10AD06 trifarotene D11AH06 crisaborole D11AX25 hydrogen peroxide G01AX17 dapivirine G02BB02 vaginal ring with progestogen G03AA17 medroxyprogesterone and estradiol G03AB09 norgestimate and ethinylestradiol G03XX Other sex hormones and modulators of the genital system G03XX01 prasterone G04CX04 fexapotide J01AA13 eravacycline J01DD18 cefteram J01DD64 cefpodoxime and beta-lactamase inhibitor J01DH06 tebipenem pivoxil J01DH52 meropenem and vaborbactam J01MA22 tosufloxacin J01MA23 delafloxacin J04AM07 rifampicin, ethambutol and isoniazid J04AM08 isoniazid, sulfamethoxazole, trimethoprim and pyridoxine J05AG06 doravirine J05AH03 peramivir J05AP57 glecaprevir and pibrentasvir J05AR23 atazanavir and ritonavir J05AR24 lamivudine, tenofovir disoproxil and doravirine J05AX17 enisamium iodide J05AX18 letermovir J05AX19 tilorone J05AX21 pentanedioic acid imidazolyl ethanamide J05AX23 ibalizumab L01AD08 uramustine L01BC09 floxuridine L01XC31 avelumab L01XC32 atezolizumab L01XE44 lorlatinib L01XE45 neratinib L01XE46 encorafenib L01XE47 dacomitinib L01XE48 icotinib L01XE50 abemaciclib L01XX58 epacadostat L01XX59 enasidenib L01XX60 talazoparib L01XX61 copanlisib L01XY01 cytarabine and daunorubicin L02AE51 leuprorelin and bicalutamide L02BB05 apalutamide L04AA38 ozanimod L04AA39 emapalumab L04AA40 cladribine 1) L04AC17 tildrakizumab M05BB09 ibandronic acid and colecalciferol N02CX08 galcanezumab N03AX24 cannabidiol N07XX12 patisiran N07XX13 valbenazine N07XX14 edaravone P01CA03 fexinidazole R03CC63 clenbuterol and ambroxol S01EX06 omidenepag S01XA26 riboflavin V04CX01 indocyanine green 1) Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04 WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 NEW DDDs valid from January 2019 ATC code ATC level name New DDD A04AD14 rolapitant 0.18 g O A05AA01 chenodeoxycholic acid 1 g O A06AH05 naldemedine 0.2 mg O A07AA08 kanamycin 3 g O A07AA10 colistin 9 MU O A07DA06 eluxadoline 0.2 g O A10AE54 insulin glargine and lixisenatide 40 U 1) P A10BK04 ertugliflozin 10 mg O A16AX15 telotristat 0.75 g O B02BX06 emicizumab 15 mg P C01CA27 droxidopa 1 g O D11AH05 dupilumab 21.4 mg P G02AD06 misoprostol 0.2 mg O G03CA03 estradiol 1.53 mg TD spray G03GA10 follitropin delta 12 mcg P G04BD13 desfesoterodine 3.5 mg O H03AA05 thyroid gland preparations 0.1 g O J01DB11 cefroxadine 2.1 g O J01DD18 cefteram 0.4 g O J01DD63 ceftriaxone and beta-lactamase inhibitor 2 g 2) P J01DH06 tebipenem pivoxil 0.56 g O J01DI03 faropenem 0.75 g O J01FA03 midecamycin 1.2 g O J01MA07 lomefloxacin 0.4 g O J01MA15 gemifloxacin 0.32 g O J01MA19 garenoxacin 0.4 g O J01MA22 tosufloxacin 0.45 g O J01MA23 delafloxacin 0.9 g O J01MA23 delafloxacin 0.6 g P J04AK06 delamanid 0.2 g O J05AC02 rimantadine 0.2 g O J05AR23 atazanavir and ritonavir 0.3 g 3) O J05AX17 enisamium iodide 1.5 g O J05AX18 letermovir 0.48 g O,P J05AX19 tilorone 0.125 g O J05AX21 pentanedioic acid imidazolyl ethanamide 90 mg O L04AA36 ocrelizumab 3.29 mg P L04AA37 baricitinib 4 mg O L04AA40 cladribine 0.34 mg O L04AC14 sarilumab 14.3 mg P L04AC16 guselkumab 1.79 mg P M09AX07 nusinersen 0.1 mg P N05AX15 cariprazine 3 mg O P01AB07 secnidazole 2 g O P01BD51 pyrimethamine, combinations 75 mg 4) P P01BE02 artemether 0.28 g R P01BE03 artesunate 0.28 g R R03DA12 mepyramine theophyllinacetate 0.6 g O R03DX08 reslizumab 7.1 mg P R03DX10 benralizumab 0.54 mg P V03AE09 patiromer calcium 8.4 g O 1) refers to insulin glargine 2) refers to ceftriaxone 3) refers to atazanavir 4) refers to pyrimethamine WHO Collaborating Centre for Drug Statistics Methodology Oslo, November 2018 .
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • List Item Withdrawal Assessment Report for Garenoxacin Mesylate
    European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 18 October 2007 Doc. Ref: EMEA/CHMP/363573/2007 WITHDRAWAL ASSESSMENT REPORT FOR Garenoxacin Mesylate (garenoxacin) EMEA/H/C/747 Day 120 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. This should be read in conjunction with th e "Question and Answer" document on the withdrawal of the application: the Assessment Report may not include all available information on the product if the CHMP assessment of the latest submitted information was still ongoing at the time of the withdrawal of the application. 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: [email protected] http://www.emea.europa.eu ©EMEA 2007 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged TABLE OF CONTENTS I. RECOMMENDATION ........................................................................................................... 3 II. EXECUTIVE SUMMARY...................................................................................................... 3 II.1 Problem statement............................................................................................. .. ..................... 3 II.2 About the product ............................................................................................. .. ..................... 4 II.3 The development programme/Compliance with
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Ladenburg Thalmann Healthcare Conference
    Ladenburg Thalmann Healthcare Conference July 13, 2021 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift in treating patients from intravenous to oral administration; the initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs, including management’s assessment of such results; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on the Company’s business and operations; the timing of the availability of data from the Company’s clinical trials; the timing of the Company’s filings with regulatory agencies; product candidate benefits; competitive position; business strategies; objectives of management; potential growth opportunities; potential market size; reimbursement matters; possible or assumed future results of operations; projected costs; and the Company’s cash forecast and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions.
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Spero Therapeutics to Present Data for All Pipeline Programs at Idweek 2020
    Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 October 16, 2020 15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will have 15 data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Presentations will cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial that evaluated Spero’s oral antibiotic investigational candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line data from the trial demonstrating that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with AP. Poster presentations include a poster on the Phase 1 clinical trial of SPR720, an oral antimicrobial investigational agent in clinical development by Spero for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. In December 2019, Spero announced
    [Show full text]
  • Company Presentation
    Company Presentation January 13, 2020 1 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs, including management’s assessment of such results; regulatory activities, including the Company’s expectation that positive results from a single pivotal Phase 3 clinical trial of Tebipenem HBr and ancillary supportive studies to be conducted in parallel with the Phase 3 trial will support the approval of Tebipenem HBr; the timing of the availability of data from the Company’s clinical trials; the timing of the Company’s filings with regulatory agencies; product candidate benefits; competitive position; business strategies; objectives of management; potential growth opportunities; potential market size; reimbursement matters; possible or assumed future results of operations; projected costs; and the Company’s cash forecast and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. All statements other than statements
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia
    THE INDONESIAN FOOD AND DRUG AUTHORITY INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY MARCH 2020 1 INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY ISBN 978-602-415-009-9 First Edition March 2020 COPYRIGHT PROTECTED BY LAW Reproduction of this book in part or whole, in any form and by any means, mechanically or electronically, including photocopies, records, and others without written permission from the publisher. This informatorium is based on information up to the time of publication and is subject to change if there is the latest data/information 2 3 FOREWORD Our praise and gratitude for the presence of God Almighty for His blessings and gifts, "The Informatorium of COVID-19 Drugs in Indonesia" has been compiled and can be published amidst the COVID-19 outbreak in Indonesia. As we know, the infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) began to plague in December 2019 in Wuhan City, Hubei Province, People's Republic of China. The disease was caused by SARS-CoV-2 infection which was later known as Coronavirus Disease 2019 (COVID-19) which in early 2020 began to spread to several countries and eventually spread to almost all countries in the world. On March 11, 2020, WHO announced COVID-19 as a global pandemic. In Indonesia, the first case was officially announced on March 2, 2020. Considering that the spread of COVID-19 has been widespread and has an impact on social, economic, defense, and public welfare aspects in Indonesia, the President of the Republic of Indonesia established the Task Force for the Acceleration of COVID- 19 Handling aiming to increase readiness and ability to prevent, detect and respond to COVID-19.
    [Show full text]
  • Clinical Pharmacology and Biopharmaceutics Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) CLINICAL PHARMACOLOGY REVIEW NDA: 200-327 Submission Date(s): • 30 Dec 2009 (SDN 1) • 30 Apr 2010 (SDN 14) • 04 Feb 2010 (SDN 7) • 18 Jun 2010 (SDN 19) • 23 Apr 2010 (SDN 10) • 06 Aug 2010 (SDN 31) • 29 Apr 2010 (SDN 13) • 18 Aug 2010 (SDN 34) Drug Ceftaroline Fosamil for Injection Trade Name TEFLARO™ (proposed) OCP Reviewer Aryun Kim, Pharm.D. OCP Team Leader Charles Bonapace, Pharm.D. PM Reviewer Yongheng Zhang, Ph.D. PM Team Leader Pravin Jadhav, Ph.D. OCP Division DCP4 OND division DAIOP (520) Sponsor Cerexa, Inc., Oakland, CA Relevant IND(s) IND 71,371 Submission Type; Code Original New Drug Application (New Molecular Entity), 1S Formulation; Strength(s) Sterile (b) (4) of ceftaroline fosamil and L-arginine supplied as powder in single-use, 20-cc, clear, Type I glass vials containing 600 mg or 400 mg of ceftaroline fosamil Indication For the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible isolates of Gram-positive and Gram-negative microorganisms Dosage and 600 mg administered every 12 hours by intravenous infusion over 1 hour Administration in patients ≥18 years of age • for 5-14 days for treatment of cSSSI • for 5-7 days for treatment of CABP 1. EXECUTIVE SUMMARY 5 1.1 Recommendations 5 1.2 Phase 4 Commitments 6 1.3 Summary of Important Clinical Pharmacology and Biopharmaceutics Findings 6 2. QUESTION-BASED REVIEW 11 2.1 General Attributes of the Drug 11 2.2 General Clinical Pharmacology 13 2.3 Intrinsic Factors 37 2.4 Extrinsic Factors 56 2.5 General Biopharmaceutics 58 2.6 Analytical Section 58 3.
    [Show full text]
  • Novel Antibiotics for Multidrug-Resistant Gram- Positive Microorganisms
    Review Novel Antibiotics for Multidrug-Resistant Gram- Positive Microorganisms Despoina Koulenti 1,2,*, Elena Xu 1, Isaac Yin Sum Mok 1,†, Andrew Song 1,†, Drosos E. Karageorgopoulos 3, Apostolos Armaganidis 2, Jeffrey Lipman 1,4,5,‡ and SotiriosTsiodras 3,‡ 1 UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia 2 2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece 3 4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece 4 Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, 4029 Brisbane, Australia 5 Anesthesiology and Critical Care, Centre Hospitalier Universitaire De Nîmes (CHU), University of Montpellier, 30029 Nîmes, France * Correspondence: [email protected] † Equal contribution-both 3rd authors. ‡ They are joint senior authors. Received: 13 July 2019; Accepted: 15 August 2019; Published: 18 August 2019 Abstract: Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future.
    [Show full text]